There were some beneficial effects compared to placebo or antidepressants but tolerability was worse .
Quetiapine was more effective than placebo treatment .
Aripiprazole and quetiapine and partly also olanzapine and risperidone augmentation showed beneficial effects compared to placebo .
Some evidence indicated beneficial effects of low-dose amisulpride for dysthymic people .
Most SGAs showed worse tolerability
BACKGROUND Major depressive disorder ( MDD ) is a common condition with a lifetime prevalence of 15 % to 18 % , which leads to considerable suffering and disability .
Some antipsychotics have been reported to induce remission in major depression , when added to an antidepressant .
OBJECTIVES To evaluate the effects of second-generation antipsychotic ( SGA ) drugs ( alone or augmentation ) compared with placebo or antidepressants for people with MDD or dysthymia .
A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
The objective of this study was to investigate whether quetiapine , when compared with placebo , can speed the onset of action and improve the quality of response to fluoxetine treatment in patients suffering from major depressive disorder . A total of 114 patients with major depressive disorder were enrolled in an 8-week treatment study . Patients were initiated on a course of fluoxetine treatment and r and omized to quetiapine or placebo . Quetiapine was flexibly dosed starting at 25 mg to a maximum of 100 mg daily . Mixed-effects regression showed that quetiapine plus fluoxetine did not achieve 50 % reduction in the Montgomery – Åsberg Depression Rating Scale score or improvement in Hamilton Anxiety Scale , Clinical Global Improvement (CGI)-Severity , and CGI-Improvement scores sooner than the fluoxetine plus placebo group ; however both groups improved in all scores over time . Mixed-effects linear regression of insomnia scores showed that the quetiapine plus fluoxetine group improved significantly more rapidly compared with the fluoxetine plus placebo group . The study indicates that quetiapine plus fluoxetine did not achieve a reduction in the Montgomery – Åsberg Depression Rating Scale score or improvement in Hamilton Anxiety Scale or CGI scores from baseline sooner than the fluoxetine plus placebo group . The combination of quetiapine and fluoxetine , however , improved sleep over fluoxetine alone over the first few weeks of treatment
There were some beneficial effects compared to placebo or antidepressants but tolerability was worse .
Quetiapine was more effective than placebo treatment .
Aripiprazole and quetiapine and partly also olanzapine and risperidone augmentation showed beneficial effects compared to placebo .
Some evidence indicated beneficial effects of low-dose amisulpride for dysthymic people .
Most SGAs showed worse tolerability
BACKGROUND Major depressive disorder ( MDD ) is a common condition with a lifetime prevalence of 15 % to 18 % , which leads to considerable suffering and disability .
Some antipsychotics have been reported to induce remission in major depression , when added to an antidepressant .
OBJECTIVES To evaluate the effects of second-generation antipsychotic ( SGA ) drugs ( alone or augmentation ) compared with placebo or antidepressants for people with MDD or dysthymia .